Inactive Instrument

Press Releases Kuros Biosciences AG Swiss Exchange

Equities

CH0011025217

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

Apr. 24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
Apr. 17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales	Apr. 24	EQ
Annual General Meeting of Kuros Biosciences approves all resolutions	Apr. 17	EQ
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023	Mar. 13	EQ
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update	Mar. 08	EQ
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference	Feb. 01	EQ
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand	Jan. 31	EQ
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04	EQ
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	Dec. 27	EQ
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages	Nov. 28	EQ
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management	23-10-12	EQ
Kuros Biosciences : Reports Results for First Half 2023	23-08-31	PU
Kuros Biosciences : Investor Webcast Presentation, H1 2023	23-08-23	PU
Kuros Biosciences "doing extremely well" in innovative spinal fusion treatments	23-08-11	AQ
Kuros Biosciences : Investor Presentation, 2023	23-08-09	PU
Kuros Biosciences Reports Results for First Half 2023	23-08-09	EQ
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	23-07-13	EQ
Kuros Biosciences : Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial	23-07-13	PU
Annual General Meeting of Kuros Biosciences approves all resolutions	23-05-08	EQ
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023	23-04-27	EQ
Kuros Biosciences : Investor Presentation 2022	23-03-19	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kuros Biosciences AG Swiss Exchange

Equities

CH0011025217

Press Releases

Filters